Is bisphosphonate therapy a risk factor for subtrochanteric femoral fractures?

David B. Burr

Research output: Contribution to journalShort survey

1 Scopus citations

Abstract

The rate of bone turnover in the femoral shaft is normally quite low. In some patients being treated with alendronate, the remodeling rate may have been excessively low. This suggests that before a patient is given a bisphosphonate, biomarkers related to bone resorption and formation should be measured.

Original languageEnglish (US)
Pages (from-to)57-58
Number of pages2
JournalJournal of the American Academy of Orthopaedic Surgeons
Volume17
Issue number1
StatePublished - Jan 1 2009

ASJC Scopus subject areas

  • Surgery
  • Orthopedics and Sports Medicine

Fingerprint Dive into the research topics of 'Is bisphosphonate therapy a risk factor for subtrochanteric femoral fractures?'. Together they form a unique fingerprint.

Cite this